Skip to main content
Erschienen in: Nuclear Medicine and Molecular Imaging 1/2017

01.08.2016 | Case Report

Unusual Horner’s Syndrome in Recurrent Breast Cancer: Evaluation Using 18F-FDG PET/CT

verfasst von: Sohyun Park, Tae Sung Kim, Seok-ki Kim

Erschienen in: Nuclear Medicine and Molecular Imaging | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is a widely used imaging modality in the initial diagnosis of cancer, treatment response evaluation and detection of recurrence. Herein, we present the case of a 39-year-old female who presented right ptosis on the follow-up of breast cancer after surgery. Clinicians suspected Horner’s syndrome, and the patient underwent FDG PET/CT for the evaluation of recurrence that could cause Horner’s syndrome. FDG PET/CT demonstrated a focal hypermetabolic lesion in the right cervicothoracic junction area, corresponding to the preganglionic cervical sympathetic trunk. A subsequent needle biopsy was done, and the lesion was confirmed as metastatic ductal carcinoma. In this case, we could detect the exact location of the recurring lesion that caused Horner’s syndrome using FDG PET/CT.
Literatur
1.
Zurück zum Zitat Jung KW, Won YJ, Kong HJ, Oh CM, Cho H, Lee DH, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2012. Cancer Res Treat. 2015;47:127–41.CrossRefPubMedPubMedCentral Jung KW, Won YJ, Kong HJ, Oh CM, Cho H, Lee DH, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2012. Cancer Res Treat. 2015;47:127–41.CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Groheux D, Espié M, Giacchetti S, Hindié E. Performance of FDG PET/CT in the clinical management of breast cancer. Radiology. 2013;266:388–405.CrossRefPubMed Groheux D, Espié M, Giacchetti S, Hindié E. Performance of FDG PET/CT in the clinical management of breast cancer. Radiology. 2013;266:388–405.CrossRefPubMed
3.
Zurück zum Zitat O JH, Choi WH, Han EJ, Choi EK, Chae BJ, Park YG, et al. The prognostic value of 18F-FDG PET/CT for early recurrence in operable breast cancer: comparison with TNM stage. Nucl Med Mol Imaging. 2013;47:263–7.CrossRefPubMedPubMedCentral O JH, Choi WH, Han EJ, Choi EK, Chae BJ, Park YG, et al. The prognostic value of 18F-FDG PET/CT for early recurrence in operable breast cancer: comparison with TNM stage. Nucl Med Mol Imaging. 2013;47:263–7.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–717. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–717.
5.
Zurück zum Zitat Metzger-Filho O, Sun Z, Viale G, Price KN, Crivellari D, Snyder RD, et al. Patterns of recurrence and outcome according to breast cancer subtypes in lymph node–negative disease: results from International Breast Cancer Study Group Trials VIII and IX. J Clin Oncol. 2013;31:3083–90.CrossRefPubMedPubMedCentral Metzger-Filho O, Sun Z, Viale G, Price KN, Crivellari D, Snyder RD, et al. Patterns of recurrence and outcome according to breast cancer subtypes in lymph node–negative disease: results from International Breast Cancer Study Group Trials VIII and IX. J Clin Oncol. 2013;31:3083–90.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Ishitobi M, Ohsumi S, Inaji H, Ohno S, Shigematsu H, Akiyama F, et al. Ipsilateral breast tumor recurrence (IBTR) in patients with operable breast cancer who undergo breast-conserving treatment after receiving neoadjuvant chemotherapy: risk factors of IBTR and validation of the MD Anderson Prognostic Index. Cancer. 2012;118:4385–93.CrossRefPubMed Ishitobi M, Ohsumi S, Inaji H, Ohno S, Shigematsu H, Akiyama F, et al. Ipsilateral breast tumor recurrence (IBTR) in patients with operable breast cancer who undergo breast-conserving treatment after receiving neoadjuvant chemotherapy: risk factors of IBTR and validation of the MD Anderson Prognostic Index. Cancer. 2012;118:4385–93.CrossRefPubMed
7.
Zurück zum Zitat Kong YX, Wright G, Pesudovs K, O’Day J, Wainer Z, Weisinger HS. Horner syndrome. Clin Exp Optom. 2007;90:336–44.CrossRefPubMed Kong YX, Wright G, Pesudovs K, O’Day J, Wainer Z, Weisinger HS. Horner syndrome. Clin Exp Optom. 2007;90:336–44.CrossRefPubMed
9.
Zurück zum Zitat Maloney WF, Younge BR, Moyer NJ. Evaluation of the causes and accuracy of pharmacologic localization in Horner’s syndrome. Am J Ophthalmol. 1980;90:394–402.CrossRefPubMed Maloney WF, Younge BR, Moyer NJ. Evaluation of the causes and accuracy of pharmacologic localization in Horner’s syndrome. Am J Ophthalmol. 1980;90:394–402.CrossRefPubMed
10.
Zurück zum Zitat Spanheimer PM, Carr JC, Thomas A, Sugg SL, Scott-Conner CE, Liao J, et al. The response to neoadjuvant chemotherapy predicts clinical outcome and increases breast conservation in advanced breast cancer. Am J Surg. 2013;206:2–7.CrossRefPubMedPubMedCentral Spanheimer PM, Carr JC, Thomas A, Sugg SL, Scott-Conner CE, Liao J, et al. The response to neoadjuvant chemotherapy predicts clinical outcome and increases breast conservation in advanced breast cancer. Am J Surg. 2013;206:2–7.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Kovacic S, Lovrencic-Huzjan A, Drpa G, Hat J, Belina S. Horner’s syndrome as an initial sign of metastatic breast cancer: case report. Cancer Detect Prev. 2007;31:450–2.CrossRefPubMed Kovacic S, Lovrencic-Huzjan A, Drpa G, Hat J, Belina S. Horner’s syndrome as an initial sign of metastatic breast cancer: case report. Cancer Detect Prev. 2007;31:450–2.CrossRefPubMed
12.
Zurück zum Zitat Tjalma WAA. Horner’s syndrome: an ominous sign in breast cancer. Eur J Obstet Gynecol Reprod Biol. 2006;126:270–1.CrossRefPubMed Tjalma WAA. Horner’s syndrome: an ominous sign in breast cancer. Eur J Obstet Gynecol Reprod Biol. 2006;126:270–1.CrossRefPubMed
13.
Zurück zum Zitat Chang EL, Lo S. Diagnosis and management of central nervous system metastases from breast cancer. The Oncol. 2003;8:398–410.CrossRef Chang EL, Lo S. Diagnosis and management of central nervous system metastases from breast cancer. The Oncol. 2003;8:398–410.CrossRef
14.
Zurück zum Zitat Groheux D, Cochet A, Humbert O, Alberini JL, Hindie E, Mankoff D. 18F-FDG PET/CT for staging and restaging of breast cancer. J Nucl Med. 2016;57(1):17s–26.CrossRefPubMed Groheux D, Cochet A, Humbert O, Alberini JL, Hindie E, Mankoff D. 18F-FDG PET/CT for staging and restaging of breast cancer. J Nucl Med. 2016;57(1):17s–26.CrossRefPubMed
Metadaten
Titel
Unusual Horner’s Syndrome in Recurrent Breast Cancer: Evaluation Using 18F-FDG PET/CT
verfasst von
Sohyun Park
Tae Sung Kim
Seok-ki Kim
Publikationsdatum
01.08.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Nuclear Medicine and Molecular Imaging / Ausgabe 1/2017
Print ISSN: 1869-3474
Elektronische ISSN: 1869-3482
DOI
https://doi.org/10.1007/s13139-016-0437-6

Weitere Artikel der Ausgabe 1/2017

Nuclear Medicine and Molecular Imaging 1/2017 Zur Ausgabe